PharmaCyte Biotech Inc (PMCB)

[Peacefulwendy]

Dr. Manuel Hidalgo joins PharmaCyte SAB
July 17, 2015 by Shane Matte

Dr.. Manuel Hidalgo, one of Europe’s leading clinical and laboratory investigators in the field of pancreatic cancer, has joined PharmaCyte Biotech’s (OTCQB:PMCB) scientific advisory board.
In a statement, CEO, Kenneth Waggoner, said Dr. Hidalgo’s “interest in our novel treatment is particularly rewarding to all of us and strongly supports our steadfast belief that it will ultimately become a breakthrough in the future treatment of pancreatic cancer.”
He said Dr. Hidalgo’s interest in using the company’s Cell-in-a-Box technology to develop treatments for other solid tumors, like liver cancer, means that his addition to our scientific advisory board could well pave the way towards a fruitful future for PharmaCyte Biotech.
In 2009, Dr. Hidalgo joined the Spanish National Cancer Research Centre where he currently heads the Gastrointestinal Cancer Clinical Research Unit. He is also a co-founder and chairman of the international Pancreatic Cancer Research Team.
Dr. Hidalgo has participated in the clinical development of more than 30 novel anticancer agents, including studies for the current gold standard to treat advanced pancreatic cancer, the combination chemotherapy of gemcitabine and Abraxane.
He also led the early clinical trials of Torisel, approved for use against advanced kidney cancer, and Tarceva, approved for use against advanced non-small cell lung cancer as well against advanced pancreatic cancer when used in combination with gemcitabine.
Dr. Hidalgo said Cell-in-Box plus low dose ifosfamide combination chemotherapy might well prove to be of great value for the development of new treatments for pancreatic and other solid tumor cancers.

http://biotuesdays.com/2015/07/17/dr-manuel-hidalgo-joins-pharmacyte-sab/